Quality of sleep in chronic migraine patients treated with fremanezumab - 6 months follow-up
Abstract
UNLABELLED: ОBJECTIVE: Sleep disturbances are frequent in patients with chronic migraine (CM). Monoclonal antibodies, such as fremanezumab, may offer better-tolerated and efficacious alternatives to traditional migraine pharmacological preventive therapies. The aim was to assess the quality of sleep (QoS) in patients with CM, during the follow-up period of 6 months, during which they were treated with fremanezumab once per month.
METHODS: The study included 82 patients with CM and 80 healthy control subjects. The study included the application of the Pittsburgh Sleep Quality Index (PSQI), Hamilton scales for the assessment of anxiety (HAM-A) and depression (HAM-D), and the 6-item Headache Impact Test (HIT-6).
RESULTS: The PSQI global score and all subscores in patients with CM were significantly higher than in the control group (p < 0.01). We noticed a statistically significant difference between the results in the PSQI global score between the first and third testing points (p < 0.01). Also, some subscores were statistically significantly better during the follow-up period. Patients with higher scores on HIT-6, HAM-A, and HAM-D had higher scores on PSQI. Higher scores on PSQI were also noticed in female patients, the elderly, and patients with higher body mass index (BMI) levels.
CONCLUSION: The prevalence of sleep disturbance in CM patients is relatively high before starting the effective prophylactic treatment. Fremanezumab therapy had a significant beneficial influence…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 82 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.